Jeffrey W. Dunn Sells 1,609 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) Director Jeffrey W. Dunn sold 1,609 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $12.43, for a total transaction of $19,999.87. Following the transaction, the director now owns 20,431 shares of the company’s stock, valued at approximately $253,957.33. This trade represents a 7.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

SI-BONE Stock Up 1.3 %

Shares of NASDAQ SIBN opened at $12.31 on Friday. The business has a 50-day moving average of $13.79 and a two-hundred day moving average of $14.23. The company has a market capitalization of $516.24 million, a price-to-earnings ratio of -13.38 and a beta of 1.22. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $21.70. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

Institutional Investors Weigh In On SI-BONE

Several large investors have recently modified their holdings of the company. Champlain Investment Partners LLC raised its holdings in shares of SI-BONE by 14.7% in the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after buying an additional 358,821 shares during the last quarter. Vanguard Group Inc. raised its stake in SI-BONE by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company’s stock valued at $40,328,000 after acquiring an additional 43,670 shares during the last quarter. American Century Companies Inc. raised its stake in SI-BONE by 22.8% during the 2nd quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock valued at $25,685,000 after acquiring an additional 368,637 shares during the last quarter. Bellevue Group AG grew its stake in shares of SI-BONE by 4.1% in the 3rd quarter. Bellevue Group AG now owns 1,444,109 shares of the company’s stock valued at $20,189,000 after purchasing an additional 56,500 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY raised its stake in shares of SI-BONE by 24.7% during the second quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company’s stock worth $17,448,000 after purchasing an additional 267,100 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on SIBN shares. Truist Financial boosted their price objective on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of SI-BONE in a research report on Wednesday. Finally, Morgan Stanley decreased their price objective on SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $23.00.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.